2387 | Humans |
1618 | Male |
1508 | Female |
1180 | Middle Aged |
1138 | Parkinson Disease |
1083 | Aged |
782 | Adult |
359 | Aged, 80 and over |
337 | Severity of Illness Index |
327 | Neurologic Examination |
279 | Antiparkinson Agents |
258 | Levodopa |
215 | Magnetic Resonance Imaging |
214 | Brain |
208 | Adolescent |
206 | Treatment Outcome |
205 | Dystonia |
204 | Animals |
182 | Movement Disorders |
159 | Tremor |
157 | Neuropsychological Tests |
152 | Dose-Response Relationship, Drug |
146 | Diagnosis, Differential |
136 | Risk Factors |
135 | Follow-Up Studies |
134 | Retrospective Studies |
133 | Double-Blind Method |
132 | Child |
125 | Electromyography |
120 | Essential Tremor |
119 | Huntington Disease |
118 | Parkinsonian Disorders |
117 | Deep Brain Stimulation |
116 | Cognition Disorders |
113 | Questionnaires |
110 | Case-Control Studies |
105 | Disability Evaluation |
104 | Dyskinesia, Drug-Induced |
104 | Disease Progression |
102 | Time Factors |
98 | Reproducibility of Results |
89 | Genetic Predisposition to Disease |
89 | Dystonic Disorders |
88 | Videotape Recording |
87 | Age of Onset |
85 | Young Adult |
85 | Mutation |
84 | Genotype |
82 | Drug Therapy, Combination |
78 | Psychomotor Performance |
78 | Dopamine |
78 | Corpus Striatum |
76 | Dementia |
73 | United States |
73 | Substantia Nigra |
73 | Functional Laterality |
71 | Drug Administration Schedule |
70 | Carbidopa |
69 | Neurons |
68 | Tourette Syndrome |
68 | Chorea |
67 | Disease Models, Animal |
66 | Torticollis |
66 | Phenotype |
66 | Cohort Studies |
66 | Activities of Daily Living |
65 | alpha-Synuclein |
65 | Parkinson Disease, Secondary |
65 | DNA Mutational Analysis |
65 | Child, Preschool |
65 | Analysis of Variance |
64 | Cerebral Cortex |
64 | Brain Mapping |
64 | Age Factors |
63 | Myoclonus |
63 | Antipsychotic Agents |
61 | Globus Pallidus |
60 | Nerve Tissue Proteins |
58 | Restless Legs Syndrome |
58 | Movement |
57 | Psychiatric Status Rating Scales |
57 | Longitudinal Studies |
56 | Quality of Life |
56 | Prospective Studies |
56 | History, 20th Century |
56 | Basal Ganglia |
55 | Prevalence |
55 | Posture |
55 | Botulinum Toxins |
54 | Muscle, Skeletal |
54 | Motor Activity |
52 | Dominance, Cerebral |
51 | Electroencephalography |
51 | Dopamine Agents |
51 | Cross-Sectional Studies |
50 | Subthalamic Nucleus |
50 | Botulinum Toxins, Type A |
50 | Atrophy |
49 | Pedigree |
48 | Motor Skills |
47 | Gait |
46 | Supranuclear Palsy, Progressive |
45 | Injections, Intramuscular |
44 | Protein-Serine-Threonine Kinases |
44 | Point Mutation |
43 | Pilot Projects |
43 | Dopamine Agonists |
43 | Depression |
42 | Family Health |
41 | Statistics, Nonparametric |
41 | Mental Status Schedule |
40 | Multiple System Atrophy |
39 | Reaction Time |
39 | Gene Frequency |
38 | Drug Combinations |
37 | Rats |
37 | Postural Balance |
37 | Incidence |
37 | Image Processing, Computer-Assisted |
37 | Cerebellum |
37 | Basal Ganglia Diseases |
36 | Sensitivity and Specificity |
36 | Putamen |
36 | Nerve Degeneration |
36 | Clinical Trials as Topic |
35 | Ubiquitin-Protein Ligases |
35 | Receptors, Dopamine |
35 | Genetic Testing |
35 | Electrodes, Implanted |
34 | Thalamus |
34 | Reference Values |
34 | Predictive Value of Tests |
33 | Tomography, X-Ray Computed |
33 | Sex Factors |
32 | Psychometrics |
32 | Mice |
32 | Hypokinesia |
32 | Gait Disorders, Neurologic |
32 | Anticonvulsants |
31 | Neuroprotective Agents |
31 | History, 19th Century |
31 | Hand |
31 | Cognition |
31 | Alleles |
30 | Positron-Emission Tomography |
30 | Polymorphism, Single Nucleotide |
30 | Odds Ratio |
30 | Lewy Bodies |
30 | Exons |
30 | Comorbidity |
30 | Biomechanical Phenomena |
29 | Neuromuscular Agents |
29 | Hallucinations |
29 | Dyskinesias |
28 | Tomography, Emission-Computed, Single-Photon |
28 | Statistics as Topic |
28 | Risk |
28 | Regression Analysis |
28 | Neural Pathways |
28 | Lewy Body Disease |
28 | Alzheimer Disease |
27 | Blepharospasm |
26 | Sleep Disorders |
26 | Psychotic Disorders |
26 | Neurodegenerative Diseases |
26 | Electric Stimulation Therapy |
26 | Caudate Nucleus |
26 | Ataxia |
25 | Trinucleotide Repeats |
25 | Tomography, Emission-Computed |
25 | Neurology |
25 | Mental Disorders |
25 | Infant |
25 | Arm |
24 | Trinucleotide Repeat Expansion |
24 | Selegiline |
24 | History, 21st Century |
24 | Handwriting |
24 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
23 | Stereotaxic Techniques |
23 | Smoking |
23 | Polymorphism, Genetic |
23 | Obsessive-Compulsive Disorder |
23 | Observer Variation |
23 | Depressive Disorder |
23 | Demography |
23 | Cross-Over Studies |
22 | Syndrome |
22 | Polysomnography |
22 | Muscle Rigidity |
22 | Genetic Linkage |
22 | Gene Expression |
22 | Chi-Square Distribution |
22 | Anti-Dyskinesia Agents |
21 | Walking |
21 | Signal Processing, Computer-Assisted |
21 | Proportional Hazards Models |
21 | Databases, Factual |
21 | Confidence Intervals |
20 | tau Proteins |
20 | Polymerase Chain Reaction |
20 | Muscle Contraction |
20 | Fatal Outcome |
20 | Epilepsies, Myoclonic |
20 | Clozapine |
20 | Brain Stem |
19 | Tic Disorders |
19 | Stereotyped Behavior |
19 | Spinocerebellar Degenerations |
19 | Postoperative Complications |
19 | Outcome Assessment (Health Care) |
19 | Olfaction Disorders |
19 | Nuclear Proteins |
19 | Logistic Models |
19 | Fingers |
19 | Chromosome Aberrations |
19 | Benzothiazoles |
19 | Attention Deficit Disorder with Hyperactivity |
19 | Aging |
18 | Spinal Cord |
18 | Randomized Controlled Trials as Topic |
18 | RNA, Messenger |
18 | Prognosis |
18 | Glycine |
18 | Genetic Variation |
18 | Biological Markers |
17 | Motor Neurons |
17 | Motor Cortex |
17 | Locomotion |
17 | Leg |
17 | Indoles |
17 | Haplotypes |
17 | Genes, Dominant |
17 | Dopamine Plasma Membrane Transport Proteins |
17 | Cerebellar Ataxia |
17 | Attention |
17 | Anxiety |
16 | Video Recording |
16 | Tyrosine 3-Monooxygenase |
16 | Tetrabenazine |
16 | Spain |
16 | REM Sleep Behavior Disorder |
16 | Pain |
16 | Neurosurgical Procedures |
16 | Neck Muscles |
16 | Music |
16 | Molecular Chaperones |
16 | Frontal Lobe |
16 | Electric Stimulation |
16 | Cerebral Infarction |
16 | Carrier Proteins |
16 | Amantadine |
15 | Pain Measurement |
15 | Occupational Diseases |
15 | Health Surveys |
15 | Fragile X Syndrome |
15 | Evoked Potentials, Motor |
15 | Combined Modality Therapy |
15 | Chromosome Mapping |
15 | Baclofen |
15 | Autonomic Nervous System Diseases |
14 | Thalamic Nuclei |
14 | Terminology as Topic |
14 | Spinocerebellar Ataxias |
14 | ROC Curve |
14 | Psychophysiologic Disorders |
14 | Mesencephalon |
14 | Macaca fascicularis |
14 | Indans |
14 | Hyperkinesis |
14 | Fluorodeoxyglucose F18 |
14 | Dihydroxyphenylalanine |
14 | Community Health Planning |
14 | Autopsy |
13 | Transcranial Magnetic Stimulation |
13 | Tics |
13 | Synucleins |
13 | Receptors, Dopamine D2 |
13 | Periodicity |
13 | Pergolide |
13 | Microelectrodes |
13 | Membrane Glycoproteins |
13 | Heterozygote Detection |
13 | Genetic Markers |
13 | European Continental Ancestry Group |
13 | Drug Tolerance |
13 | Dopamine Antagonists |
13 | Central Nervous System Stimulants |
13 | Bromocriptine |
13 | Brain Diseases |
13 | Administration, Oral |
12 | Thiazoles |
12 | Recurrence |
12 | Rats, Sprague-Dawley |
12 | Radiopharmaceuticals |
12 | Mood Disorders |
12 | Monoamine Oxidase Inhibitors |
12 | Minnesota |
12 | Machado-Joseph Disease |
12 | Isometric Contraction |
12 | Hepatolenticular Degeneration |
12 | Health Status |
12 | Genetic Therapy |
12 | Gene Expression Regulation |
12 | Europe |
12 | Dysarthria |
12 | Dibenzothiazepines |
12 | Diagnostic and Statistical Manual of Mental Disorders |
12 | Cross-Cultural Comparison |
12 | Conversion Disorder |
12 | Chromosome Disorders |
12 | Blinking |
12 | Athetosis |
12 | Accidental Falls |
11 | gamma-Aminobutyric Acid |
11 | Ventral Thalamic Nuclei |
11 | Single-Blind Method |
11 | Serotonin Uptake Inhibitors |
11 | Serine |
11 | Sensation Disorders |
11 | Schizophrenia |
11 | Psychomotor Disorders |
11 | Piracetam |
11 | Neurotoxins |
11 | Neural Inhibition |
11 | Nerve Net |
11 | Mitochondria |
11 | Memory |
11 | Magnetic Resonance Spectroscopy |
11 | Intracellular Signaling Peptides and Proteins |
11 | Infusions, Intravenous |
11 | Hypoxia, Brain |
11 | Genetic Association Studies |
11 | Fragile X Mental Retardation Protein |
11 | Exercise |
11 | Ethnic Groups |
11 | Encephalitis |
11 | Dystonia Musculorum Deformans |
11 | Delayed-Action Preparations |
11 | DNA-Binding Proteins |
11 | DNA Primers |
11 | Cues |
11 | Arousal |
11 | Apomorphine |
11 | Algorithms |
10 | Verbal Behavior |
10 | Stereotypic Movement Disorder |
10 | Speech Disorders |
10 | Serotonin |
10 | Receptors, N-Methyl-D-Aspartate |
10 | Psychoses, Substance-Induced |
10 | Proprioception |
10 | Oxidative Stress |
10 | Oncogene Proteins |
10 | Olivopontocerebellar Atrophies |
10 | New York City |
10 | Muscle Relaxants, Central |
10 | Monoamine Oxidase |
10 | Membrane Transport Proteins |
10 | Mass Screening |
10 | Jews |
10 | International Cooperation |
10 | Homovanillic Acid |
10 | Hemifacial Spasm |
10 | Hand Strength |
10 | Friedreich Ataxia |
10 | Feasibility Studies |
10 | Fatigue |
10 | Factor Analysis, Statistical |
10 | Facial Muscles |
10 | Exhibits as Topic |
10 | Diagnosis, Computer-Assisted |
10 | Deglutition Disorders |
10 | Compulsive Behavior |
10 | Cocaine |
10 | Chronic Disease |
10 | Biomedical Research |
10 | Anxiety Disorders |
10 | Affect |
9 | Weight-Bearing |
9 | Voice Disorders |
9 | Ubiquitin |
9 | Thalamic Diseases |
9 | Substance Withdrawal Syndrome |
9 | Stroke |
9 | Somatosensory Cortex |
9 | Somatoform Disorders |
9 | Rest |
9 | Purkinje Cells |
9 | Protein Kinases |
9 | Pregnancy |
9 | Placebos |
9 | Photic Stimulation |
9 | Patient Selection |
9 | Patient Satisfaction |
9 | Ocular Motility Disorders |
9 | Neck |
9 | Muscles |
9 | Muscle Cramp |
9 | Motor Neuron Disease |
9 | Linear Models |
9 | Intellectual Disability |
9 | Injections, Subcutaneous |
9 | Impulse Control Disorders |
9 | Imaging, Three-Dimensional |
9 | Heterozygote |
9 | Heart Rate |
9 | Glutamic Acid |
9 | Glucose |
9 | Germany |
9 | Gastrointestinal Diseases |
9 | France |
9 | Fourier Analysis |
9 | Executive Function |
9 | Energy Metabolism |
9 | Electrocardiography |
9 | Diseases in Twins |
9 | Data Interpretation, Statistical |
9 | Constipation |
9 | Clonazepam |
9 | Chromosome Deletion |
9 | Cerebral Palsy |
9 | Caregivers |
9 | Biopsy |
9 | Autoantibodies |
9 | Apraxias |
9 | Antioxidants |
9 | Antidepressive Agents |
9 | Amyloid beta-Peptides |
8 | Wrist |
8 | Visual Perception |
8 | Tongue |
8 | Smell |
8 | Sex Distribution |
8 | Reverse Transcriptase Polymerase Chain Reaction |
8 | Rats, Inbred Strains |
8 | Pyramidal Tracts |
8 | PubMed |
8 | Psychomotor Agitation |
8 | Proteins |
8 | Piperazines |
8 | Orientation |
8 | Nitriles |
8 | Neuronal Plasticity |
8 | Neuroglia |
8 | Mutation, Missense |
8 | Muscle Weakness |
8 | Microsatellite Repeats |
8 | Mice, Inbred C57BL |
8 | Medical Records |
8 | MPTP Poisoning |
8 | Long-Term Care |
8 | Linkage Disequilibrium |
8 | Kaplan-Meier Estimate |
8 | Iron |
8 | Hydroxyindoleacetic Acid |
8 | Hippocampus |
8 | Head |
8 | Guidelines as Topic |
8 | Gene Deletion |
8 | Fetal Tissue Transplantation |
8 | Ergolines |
8 | Environmental Exposure |
8 | Drug Interactions |
8 | Disorders of Excessive Somnolence |
8 | Diffusion Magnetic Resonance Imaging |
8 | Data Collection |
8 | DNA, Mitochondrial |
8 | Coffee |
8 | Cerebellar Diseases |
8 | Catechols |
8 | Catechol O-Methyltransferase Inhibitors |
8 | Brain Neoplasms |
8 | Brain Injuries |
8 | Bipolar Disorder |
8 | Autoimmune Diseases |
8 | Aspartic Acid |
8 | Arginine |
8 | Apolipoproteins E |
8 | Akathisia, Drug-Induced |
8 | Action Potentials |
8 | Acoustic Stimulation |
7 | Thiophenes |
7 | Tetrahydronaphthalenes |
7 | Teaching |
7 | Task Performance and Analysis |
7 | Survival Analysis |
7 | Stress, Psychological |
7 | Sickness Impact Profile |
7 | Siblings |
7 | Sex Characteristics |
7 | Sensory Thresholds |
7 | Pyridines |
7 | Psychological Tests |
7 | Postoperative Period |
7 | Postmortem Changes |
7 | Personality Inventory |
7 | Peripheral Nerves |
7 | Parietal Lobe |
7 | Pantothenate Kinase-Associated Neurodegeneration |